GSNOR Inhibition for Treatment of Parkinsonís Disease
Rapid Response Innovation Awards, 2014
Study Rationale: † † † † † † † † † †
Parkinsonís disease may be driven by inflammation and toxic, reactive products from oxygen metabolism. SAJE Pharmaís drugs target an enzyme called s-nitrosoglutathione reductase (GSNOR) to inhibit both of those toxic processes, which may slow Parkinsonís progression.†
SAJE Pharma seeks to learn if its drug can enter the brain and can inhibit Parkinsonís in a pre-clinical disease model.
SAJE Pharma will first determine which of its drugs are predicted by a computer model to enter the brain and then measure whether those drugs do, in fact, enter the brain. The best of those brain-entering drugs will be tested in a model of Parkinsonís disease to evaluate its impact.
Impact on Diagnosis/Treatment of Parkinsonís Disease: † † † † † † † ††
If our study proves that one of our drugs can inhibit Parkinsonís disease in a pre-clinical model, we will have a reason to move toward clinical testing of this potential treatment for the disease.
Next Steps for Development:
If this study is successful, we will need to confirm it in a second pre-clinical study. If that study is also successful, we will then start toxicity and safety studies to get the drug ready for clinical trials with Parkinsonís patients.
Chairman, President and Chief Technical Officer at SAJE Pharma, LLC
Location: Baltimore, Maryland, United States